Your browser doesn't support javascript.
loading
Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high-dose methotrexate, and R-DHAP followed by autologous stem cell transplantation: results of the HOVON 80 phase 2 study.
Doorduijn, Jeanette K; van Imhoff, Gustaaf W; van der Holt, Bronno; Schouten, Harry C; Schaafsma, Martijn R; MacKenzie, Marius A; Baars, Joke W; Kersten, Marie José; Lugtenburg, Pieternella J; van den Bent, Martin J; Enting, Roelien H; Spoelstra, Fokje M; Poortmans, Philip; Bromberg, Jacoline E C.
Afiliación
  • Doorduijn JK; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
  • van Imhoff GW; Department of Hematology, University Medical Center Groningen, Groningen, The Netherlands.
  • van der Holt B; HOVON Data Center, Erasmus MC Cancer Institute-Clinical Trial Center, Rotterdam, The Netherlands.
  • Schouten HC; Department of Internal Medicine, Maastricht University Medical Center, Maastricht, The Netherlands.
  • Schaafsma MR; Department of Internal Medicine, Medisch Spectrum Twente, Enschede, The Netherlands.
  • MacKenzie MA; Department of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Baars JW; Department of Medical Oncology, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
  • Kersten MJ; Department of Hematology, Academic Medical Center, Amsterdam, The Netherlands.
  • Lugtenburg PJ; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
  • van den Bent MJ; Department of Neuro-oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
  • Enting RH; Department of Neurology, University Medical Center Groningen, Groningen, The Netherlands.
  • Spoelstra FM; HOVON Data Center, Erasmus MC Cancer Institute-Clinical Trial Center, Rotterdam, The Netherlands.
  • Poortmans P; Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Bromberg JEC; Department of Neuro-oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Hematol Oncol ; 35(4): 497-503, 2017 Dec.
Article en En | MEDLINE | ID: mdl-27530779
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Trasplante Autólogo / Linfoma no Hodgkin / Protocolos de Quimioterapia Combinada Antineoplásica / Metotrexato / Neoplasias del Sistema Nervioso Central / Trasplante de Células Madre Hematopoyéticas / Rituximab Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Hematol Oncol Año: 2017 Tipo del documento: Article País de afiliación: Países Bajos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Trasplante Autólogo / Linfoma no Hodgkin / Protocolos de Quimioterapia Combinada Antineoplásica / Metotrexato / Neoplasias del Sistema Nervioso Central / Trasplante de Células Madre Hematopoyéticas / Rituximab Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Hematol Oncol Año: 2017 Tipo del documento: Article País de afiliación: Países Bajos